Document Type : Original Article
Keywords
| 1. |
Bystritsky A, Liberman RP, Hwang S, Wallace CJ, Vapnik T, Maindment K, et al. Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders. Depress Anxiety 2001;14:214-8. ![]() [PUBMED] |
| 2. | |
| 3. | |
| 4. | |
| 5. | |
| 6. | |
| 7. |
Nedeljkovic M, Moulding R, Kyrios M, Doron G. The relationship of cognitive confidence to OCD symptoms. J Anxiety Disord 2009;23:463-8. ![]() [PUBMED] |
| 8. |
Hermesh H, Masser-Kavitzky R, Gross-Isseroff R. Obsessive-compulsive disorder and Jewish religiosity. J Nerv Ment Dis 2003;191:201-3. ![]() [PUBMED] |
| 9. |
Sica C, Novara C, Sanavio E. Religiousness and obsessive-compulsive cognitions and symptoms in an Italian population. Behav Res Ther 2002;40:813-23. ![]() [PUBMED] |
| 10. |
Tek C, Ulug B. Religiosity and religious obsessions in obsessive-compulsive disorder. Psychiatry Res 2001;104:99-108. ![]() [PUBMED] |
| 11. | |
| 12. |
Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence. J Clin Psychiatry 2004;65 (Suppl 14):11-7. ![]() [PUBMED] |
| 13. |
Joel D, Doljansky J. Selective alleviation of compulsive lever-pressing in rats by D1, but not D2, blockade: Possible implications for the involvement of D1 receptors in obsessive-compulsive disorder. Neuropsychopharmacology 2003;28:77-85. ![]() [PUBMED] |
| 14. | |
| 15. |
Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics 2008;2:62-75. ![]() [PUBMED] |
| 16. | |
| 17. |
Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006;3:69-81. ![]() [PUBMED] |
| 18. |
Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction - Newer targets for anti-obsessional drugs. Recent Pat CNS Drug Discov 2007;2:47-55. ![]() [PUBMED] |
| 19. |
Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 2006;29:553-84, xi. ![]() [PUBMED] |
| 20. | |
| 21. |
Huppert JD, Schultz LT, Foa EB, Barlow DH, Davidson JR, Gorman JM, et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry 2004;161:1485-7. ![]() [PUBMED] |
| 22. |
Bland RC, Newman SC, Orn H. Age and remission of psychiatric disorders. Can J Psychiatry 1997;42:722-9. ![]() [PUBMED] |
| 23. | |
| 24. | |
| 25. | |
| 26. | |
| 27. |
Braga DT, Cordioli AV, Niederauer K, Manfro GG. Cognitive-behavioral group therapy for obsessive-compulsive disorder: A 1-year follow-up. Acta Psychiatr Scand 2005;112:180-6. ![]() [PUBMED] |
| 28. | |
| 29. |
Kendall PC, Southam-Gerow MA. Long-term follow-up of a cognitive-behavioral therapy for anxiety-disordered youth. J Consult Clin Psychol 1996;64:724-30. ![]() [PUBMED] |